EurekaMag
+ Translate
+ Most Popular
Sobre os generos Lopadusa Stal e Bothrocoris Mayr (Hemiptera, Pentatomidae, Pentatomini)
RFEF pilot plant for inactivation of Escherichia coli in apple juice
Calpionella alpina Lorenz als "Leitfossil"
Sooretama: The Atlantic Rain Forest of Brazil. Francis Dov Por
Novel approaches in myeloma therapy
Preliminary Notes on the Study of Mitochondria During the 1st Stages of the Destruction of Cadavers
A preliminary study of the biology of lichee stink bug, Tessaratoma papulosa Drury, and its control
The status of the Sabu Island python - Die Situation des Savu-Pythons
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. the UK Group for Immunoglobulin Replacement therapy in Multiple Myeloma
Conflicts between children
Clinical presentations in neuropsychiatry
Method of suturing a perforated ulcer of the stomach and duodenum
Identification of mechanical asphyxiation in cases of attempted masking of the homicide
Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
Is it warm? Is it real? Or just low spatial frequency?
Additions and corrections to the list of Korean Heteroptera
Factors contributing to the maintenance of oligotrophy in an alpine glacial moraine lake (Wallowa lake) in Northeast Oregon
Classification, paleoecology, and biostratigraphy of crinoids from the Stull Shale (Late Pennsylvanian) of Nebraska, Kansas, and Iowa
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Neue Formen der Bauchsammler aus Turkmenien (Hymenoptera, Apoidea)
Atypische Hühnerpest und Newcastle-Krankheit. Ein Identifizierungsversuch
Parasitellus fucorum in the debris of Apis mellifera - a risk of confusion with Tropilaelaps spp
Applying the Technology Acceptance Model to the introduction of healthcare information systems
Ein akarologischer Nachruf für den "Roland"
Mutation research on crop plants in Argentina

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial


The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial



Trials 19(1): 169



ISSN/ISBN: 1745-6215

PMID: 29514706

DOI: 10.1186/s13063-018-2524-8

Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all patients will relapse post first-line autologous stem cell transplantation (ASCT). First relapse management (second-line treatment) has evolved in recent years with an expanding portfolio of novel agents, driving response rates influencing the durability of response. A second ASCT, as part of relapsed disease management (salvage ASCT), has been shown to prolong the progression-free survival and overall survival following a proteasome inhibitor-containing re-induction regimen, in the Cancer Research UK-funded National Cancer Research Institute Myeloma X (Intensive) study. It is now recommended that salvage ASCT be considered for suitable patients by the International Myeloma Working Group and the National Institute for Health and Care Excellence NG35 guidance. ACCoRd (Myeloma XII) is a UK-nationwide, individually randomised, multi-centre, multiple randomisation, open-label phase III trial with an initial single intervention registration phase aimed at relapsing MM patients who have received ASCT in first-line treatment. We will register 406 participants into the trial to allow 284 and 248 participants to be randomised at the first and second randomisations, respectively. All participants will receive re-induction therapy until maximal response (four to six cycles of ixazomib, thalidomide and dexamethasone). Participants who achieve at least stable disease will be randomised (1:1) to receive either ASCTCon, using high-dose melphalan, or ASCTAug, using high-dose melphalan with ixazomib. All participants achieving or maintaining a minimal response or better, following salvage ASCT, will undergo a second randomisation (1:1) to consolidation and maintenance or observation. Participants randomised to consolidation and maintenance will receive consolidation with two cycles of ixazomib, thalidomide and dexamethasone, and maintenance with ixazomib until disease progression. The question of how best to maximise the durability of response to salvage ASCT warrants clinical investigation. Given the expanding scope of oral therapeutic agents, patient engagement with long-term maintenance strategies is a real opportunity. This study will provide evidence to better define post-relapse treatment in MM. ISRCTN, ISRCTN10038996 . Registered on 15 December 2016.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 072748113

Download citation: RISBibTeXText

Related references

Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Bone Marrow Transplantation 50(10): 1306-1311, 2015

Maintenance Therapy with the Oral Proteasome Inhibitor (Pi) Ixazomib Significantly Prolongs Progression-Free Survival (Pfs) Following Autologous Stem Cell Transplantation (Asct) in Patients with Newly Diagnosed Multiple Myeloma (Ndmm): Phase 3 Tourmaline-Mm3 Trial. Biology of Blood and Marrow Transplantation 25(3): S19-S20, 2019

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group. European Journal of Haematology 108(1): 34-44, 2022

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRi Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. LANCET. Oncology 15(8): 874-885, 2014

Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. Journal of Clinical Oncology 24(18_Suppl): 7546-7546, 2016

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma. Advances in Hematology 2014: 652395, 2014

BEAM Vs Melphalan Based Conditioning Therapy for Second Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). Biology of Blood and Marrow Transplantation 20(2): S112-S113, 2014

Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase i trial. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 18(9): 1455-1461, 2012

Combination of IFN-α/Gm-CSF as a Maintenance therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): a Prospective Phase Ii Study. Clinical Medicine Insights. Oncology 4: 117-125, 2010

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. LANCET. Haematology 3(7): E340-E351, 2016

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase Ii HOVON-126/NMSG 21.13 trial. Haematologica 105(12): 2879-2882, 2020

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica 2020, 2020

Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 17(11): 1638-1645, 2011

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37(19): 1617-1628, 2019

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer Journal 10(5): 53, 2020